PharmaVoice

AUGUST 3, 2022

How these latest executive personnel changes are impacting the industry.

264

264

PhRMA

AUGUST 3, 2022

As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local media outlets about the potential consequences.

246

246

Pharmacy Times

AUGUST 4, 2022

American Diabetes Association updates recommendations regarding SGLT-2 inhibitors, GLP-1 RA, and finerenone for cardiovascular and renal comorbidities.

153

153

Pharmaceutical Technology

AUGUST 4, 2022

Soaring patient numbers are stretching hospital capacity across the globe, forcing healthcare providers and their partners to think laterally about how to meet the demand without doubling their resources. Smarter diagnostic tools and more sophisticated remote- and self-care models will have an increasingly important role to play, as long as any advances are seen to deliver excellent outcomes and a better patient experience.

Hospitals 143

Hospitals 143

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

PharmaVoice

AUGUST 2, 2022

How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

264

264

PhRMA

AUGUST 5, 2022

The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t the facts. Here, we bust those myths.

147

147

pharmaphorum

AUGUST 3, 2022

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back? It’s been more than two decades since the ground-breaking potential of using electronic health records (EHR) to inform clinical research was first mooted. Since then, progress has been slow, but the industry now has everything it needs to close the feedback loop between science, evidence, and care, said speakers at a recent Co

Cerner 124

Cerner FDA 124

PharmaVoice

AUGUST 4, 2022

Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

246

246

PhRMA

AUGUST 4, 2022

I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal.

147

147

Pharmacy Times

AUGUST 3, 2022

Effective pharmacy managers help everyone to see the proverbial forest through the trees.

149

149

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

European Pharmaceutical Review

AUGUST 1, 2022

Dubbed Disability Diversity in Clinical Trials (DDiCT), the initiative aims to provide recommendations on how to improve access, engagement, speed of enrolment and participation of people with disabilities in clinical trials. The goal is to “ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies,” a statement said.

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies FDA 122

PharmaVoice

AUGUST 1, 2022

WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

246

246

PhRMA

AUGUST 2, 2022

In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. To celebrate, we are reflecting on the history of the program that benefits more than 60 million Americans. Unfortunately, some members of Congress are considering significant changes to Medicare that could have a devastating effect on millions of Americans.

130

130

Pharmacy Times

AUGUST 3, 2022

Findings in a new trial show that dietary supplementation of resistant starch has the potential to decrease people’s risk of certain types of gastrointestinal cancers.

149

149

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates. A bivalent booster candidate, the mRNA-1273.222 vaccine comprises Spikevax along with the Omicron BA.4/5 strain messenger RNA (mRNA).

Vaccines 115

Vaccines FDA 115

PharmaVoice

AUGUST 1, 2022

Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

246

246

PhRMA

AUGUST 3, 2022

Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines , American medical innovation and our health care system as a whole. But there is another consequence that we can’t leave out: the impact this proposal will have on the biopharmaceutical industry’s contributions to American jobs and the economy.

113

113

Pharmacy Times

AUGUST 1, 2022

Many companies overlook the power that workplace culture can have on employee wellness and instead, focus relentlessly on financial metrics.

145

145

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

PharmExec

AUGUST 5, 2022

Court Horncastle discusses how his career led him to work with treating COPD and asthma.

111

111

PharmaVoice

AUGUST 3, 2022

The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

130

130

Pharmaceutical Technology

AUGUST 4, 2022

North America extended its dominance for machine learning hiring among pharmaceutical industry companies in the three months ending May. The number of roles in North America made up 63.9% of total machine learning jobs - up from 62.6% in the same quarter last year. That was followed by Europe, which saw a 0.6 year-on-year percentage point change in machine learning roles.

105

105

Pharmacy Times

AUGUST 2, 2022

Over the next few years, undiagnosed breast cancer cases may add to the demand for more rigorous end-stage treatments and therapeutics.

144

144

pharmaphorum

AUGUST 2, 2022

Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulation in a phase 3 trial. The results of the IMscin001 study found that an injection of Tecentriq under the skin taking just a few minutes was non-inferior to a 30 to 60-minute infusion with the IV version in terms of pharmacokinetics – how the active ingredient behaves in the body after administration.

Chemotherapy 105

Chemotherapy FDA 105

European Pharmaceutical Review

AUGUST 3, 2022

Ph. Eur. The European Pharmacopoeia (Ph. Eur.) Commission has established the mRNAVAC Working Party to begin working on quality standards to support the emerging field of messenger RNA (mRNA) vaccines. The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Last year, the companies entered a strategic collaboration. Subsequently, technology transfer as well as scale-up from the lab bench to the commercial facility of Samsung were carried out in a period of seven months.

Vaccines 104

Vaccines 104

Pharmacy Times

AUGUST 2, 2022

Health care facilities in counties with higher Black populations and in rural areas were less likely to serve as COVID-19 vaccination facilities during May 2021, indicating disparities in vaccine distribution.

Vaccines 139

Vaccines 139

pharmaphorum

AUGUST 1, 2022

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to making it available in sometime around the middle of 2023. The US biotech – which already has three antisense drugs for DMD on the market – had said earlier it was planning to delay the application into 2023, so the new announcement marks an acceleration of its plans.

FDA 105

FDA 105

European Pharmaceutical Review

AUGUST 1, 2022

Researchers have developed microparticles that can be tuned to deliver their payload at different time points. According to the authors, the technology could enable the creation of “self-boosting” vaccines that only need to be administered once, which could be particularly beneficial for childhood vaccinations in regions with limited access to medical care.

Vaccines 105

Vaccines Immunization 105

Outsourcing Pharma

AUGUST 2, 2022

A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.

102

102

Pharmacy Times

AUGUST 2, 2022

Using computational methods, the development of an HIV therapy cocktail based on the virus’ genetics was found to increase the efficacy of treatment.

139

139

pharmaphorum

AUGUST 4, 2022

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy studies can be a hit-and-miss affair. The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had seen disease progression despite earlier treatment with an anti-h

Chemotherapy 105

Chemotherapy Labelling FDA 105

European Pharmaceutical Review

AUGUST 1, 2022

The joint Big Data Steering Group of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) has published a third workplan, setting actions to be delivered by 2025. According to EMA, the new plan will further enhance the efficient integration of data analysis into the regulatory evaluation of medicinal products. “Using novel technologies and the evidence generated from big data will benefit public health by accelerating medicine development, improving treatment outcomes an

Documentation 105

Documentation 105

Pharmaceutical Technology

AUGUST 1, 2022

AbbVie has reported net revenues of $14.6bn for the second quarter (Q2) of 2022 as against $14bn in the year-ago quarter, indicating a 4.5% rise on a GAAP basis. Net revenue surged by 6.1% on an operational basis during the quarter. The GAAP diluted earnings per share (EPS) for the quarter ended 30 June grew by 21.4% to 0.51 from $0.42 in Q2 2021. An 11.2% surge in adjusted diluted EPS of $3.37 was reported in Q2 this year against $3.03 in the prior-year quarter.

98

98